Screening for Illicit Drug Use, Including Nonmedical Use of Prescription Drugs: an Updated Systematic Review for the U.S

Total Page:16

File Type:pdf, Size:1020Kb

Screening for Illicit Drug Use, Including Nonmedical Use of Prescription Drugs: an Updated Systematic Review for the U.S Evidence Synthesis Number 186 Screening for Illicit Drug Use, Including Nonmedical Use of Prescription Drugs: An Updated Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00007-I-EPC5, Task Order No. 2 Prepared by: Kaiser Permanente Research Affiliates Evidence-based Practice Center Kaiser Permanente Center for Health Research Portland, OR Investigators: Carrie D. Patnode, PhD, MPH Leslie A. Perdue, MPH Megan Rushkin, MPH Elizabeth A. O’Connor, PhD AHRQ Publication No. 19-05255-EF-1 August 2019 This report is based on research conducted by the Kaiser Permanente Research Affiliates Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2015-00007-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. The final report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report. Acknowledgments The authors gratefully acknowledge the following individuals for their contributions to this project: Kathleen Irwin, MD, MPH, David Meyers, MD, MPH, Ernest Sullivent, MD, MPH, and Amanda Borsky, DrPH, MPP, at AHRQ; current and former members of the U.S. Preventive Services Task Force who contributed to topic deliberations; Richard Saitz, MD, MPH, at Boston University Schools of Medicine and Public Health for his content expertise and review of the draft report; Cheryl Arratoon, MSc, Sharon Levy, MD, MPH, Jennifer McNeely, MD, MS, Natalie Mercer, PhD, Steven Ondersma, PhD, MA, Brad Stein, MD, PhD, Adrienne Stevens, PhD, and Matthew Young, PhD, for providing expert review of the draft report; Christina Mikosz, MD, MPH, Jean Ko, PhD, and Rebecca DelCarmen-Wiggins, PhD, for providing federal review of the report; and Smyth Lai, MLS, and Katherine Essick, BS, at the Kaiser Permanente Center for Health Research for technical and editorial assistance. Screening for Illicit Drug Use ii Kaiser Permanente Research Affiliates EPC Structured Abstract Objective: We conducted this systematic review to support the U.S. Preventive Services Task Force in updating its 2008 recommendation on screening adolescents and adults, including pregnant women, for illicit drug use. Our review addressed 5 key questions (KQ): 1a. Does primary care screening for drug use in adolescents and adults, including pregnant women, reduce drug use or improve other risky behaviors? 1b. Does primary care screening for drug use in adolescents and adults, including pregnant women, reduce morbidity or mortality or improve other health, social, or legal outcomes? 2. What is the accuracy of drug use screening instruments? 3. What are the harms of primary care screening for drug use in adolescents and adults, including pregnant women? 4a. Do counseling interventions to reduce drug use, with or without referral, reduce drug use or improve other risky behaviors in screen-detected persons? 4b. Do counseling interventions to reduce drug use, with or without referral, reduce morbidity or mortality or improve other health, social, or legal outcomes in screen-detected persons? 5. What are the harms of interventions to reduce drug use in screen-detected persons? Data Sources: We performed a search of MEDLINE, PubMed Publisher-Supplied, PsycINFO, and the Cochrane Central Register of Controlled Trials for studies published through June 7, 2018. Studies included in three related USPSTF reviews were re-evaluated for potential inclusion. We supplemented searches by examining reference lists from related articles and expert recommendations and searched federal and international trial registries for ongoing trials. Study Selection: Two researchers reviewed 17,919 titles and abstracts and 271 full-text articles against prespecified inclusion criteria. For all KQs, we included studies among adolescents and adults aged 12 years and older, including pregnant women. Studies targeting illicit psychoactive drug use or nonmedical pharmaceutical drug use were included; those targeting nonpsychoactive drugs (e.g., laxatives, anabolic steroids) were excluded. For KQs 1 and 3, we included studies that compared individuals who received screening with those who received no screening or who received usual care, including randomized trials or nonrandomized controlled trials. For KQ 2, we included studies that reported the accuracy (sensitivity and specificity) of standardized screening instruments compared with structured clinical interviews or biologic verification and that took place in a setting that was applicable to primary care. For KQ 4 and 5 about counseling interventions, only randomized and nonrandomized trials among screen-detected persons were included. Trials among persons who sought drug treatment or were referred or mandated to receive drug treatment were excluded. Interventions could include any brief counseling approach designed to reduce drug use, with or without referral. Studies of medication-assisted therapy (i.e., the use of methadone, buprenorphine, or naltrexone plus counseling) to treat opioid use disorders were excluded given that use of this therapy limited to adults with a diagnosed opioid use disorder (typically severe and non-screen detected). We conducted dual, independent critical appraisal of all provisionally included studies and abstracted all important study details and results from all studies rated fair or good quality. Data were abstracted by one reviewer and confirmed by another. Data Analysis: We synthesized data separately for each KQ and subpopulation (i.e., adolescents, young adults and adults, and pregnant and postpartum women). The data for KQ 2 did not allow for quantitative pooling due to the limited number of contributing studies for each screening instrument and condition, so we synthesized the data qualitatively through tables and narrative Screening for Illicit Drug Use iii Kaiser Permanente Research Affiliates EPC synthesis. For drug use outcomes, we ran random effects meta-analyses using the DerSimonian and Laird method to calculate the pooled differences in mean changes in drug use days; data was too sparse to pool for binary data on drug abstinence. We examined statistical heterogeneity among the pooled studies using standard χ2 tests and estimated the proportion of total variability in point estimates using the I2 statistic. We graded the strength of the overall body of evidence based on the consistency and precision of the results, reporting bias, and study quality. Results: We found no evidence that addressed the benefits and harms of screening for drug use. Twenty-eight studies (n=65,720) addressed the accuracy of 30 drug use screening instruments; each specific screening instrument has not been studied more than once or twice. Studies among adolescents mainly focused on detecting cannabis use. They found that sensitivity for detecting any cannabis use or unhealthy cannabis use of frequency-based and risk assessment screen tools (all validated against structured clinical interview alone) ranged from 0.68 to 0.98 (95% CI range, 0.64 to 0.99) and specificity ranging from 0.82 to 1.00 (95% CI range, 0.80 to 1.00). Among adults, frequency-based and risk assessment drug screening tools (all but two validated against structured clinical interview alone) showed sensitivity for detecting unhealthy use of any drug ranging from 0.71 to 0.94 (95% CI range, 0.62 to 0.97) and specificity ranging from 0.87 to 0.97 (95% CI range, 0.83 to 0.98). For identifying drug use disorders among adults, sensitivity ranged from 0.85 to 1.00 (95% CI range, 0.67 to 1.00) and specificity ranged from 0.67 to 0.93 (95% CI, 0.58 to 0.95) when using the same cutoffs. Sensitivity for detecting any prenatal drug use using frequency-based and risk assessment (all validated against hair or urine analyses) was lower than the estimates for any drug use in non-pregnant adults (only rarely based on validation against biologic samples) and ranged from 0.37 to 0.76 (95% CI range, 0.24 to 0.86). Specificity was comparable and ranged from 0.68 to 0.83 (95% CI range, 0.55 to 0.91). We included 27 trials that addressed the effectiveness of a counseling intervention on changes in drug use or improved health, social, or legal outcomes among a screen-detected population. Across all 27 trials (n analyzed=8705), in general, there was no consistent effect of the interventions on rates of self-reported or biologically confirmed drug use at 3- to 12-month followup. Likewise, across 13 trials reporting the effects of the interventions on health, social, or legal outcomes (n- analyzed=4304), none of the trials found a statistically significant difference between intervention and control groups on any of these measures at 3- to 12-month followup.
Recommended publications
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • What Are the Treatments for Heroin Addiction?
    How is heroin linked to prescription drug abuse? See page 3. from the director: Research Report Series Heroin is a highly addictive opioid drug, and its use has repercussions that extend far beyond the individual user. The medical and social consequences of drug use—such as hepatitis, HIV/AIDS, fetal effects, crime, violence, and disruptions in family, workplace, and educational environments—have a devastating impact on society and cost billions of dollars each year. Although heroin use in the general population is rather low, the numbers of people starting to use heroin have been steadily rising since 2007.1 This may be due in part to a shift from abuse of prescription pain relievers to heroin as a readily available, cheaper alternative2-5 and the misperception that highly pure heroin is safer than less pure forms because it does not need to be injected. Like many other chronic diseases, addiction can be treated. Medications HEROIN are available to treat heroin addiction while reducing drug cravings and withdrawal symptoms, improving the odds of achieving abstinence. There are now a variety of medications that can be tailored to a person’s recovery needs while taking into account co-occurring What is heroin and health conditions. Medication combined with behavioral therapy is particularly how is it used? effective, offering hope to individuals who suffer from addiction and for those around them. eroin is an illegal, highly addictive drug processed from morphine, a naturally occurring substance extracted from the seed pod of certain varieties The National Institute on Drug Abuse (NIDA) has developed this publication to Hof poppy plants.
    [Show full text]
  • DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance
    ALCOHOL & OTHER DRUG SERVICES DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance Use Disorder See DSM-5 for criteria specific to the drugs identified as primary, secondary or tertiary. P S T (P=Primary, S=Secondary, T=Tertiary) 1. Substance is often taken in larger amounts and/or over a longer period than the patient intended. 2. Persistent attempts or one or more unsuccessful efforts made to cut down or control substance use. 3. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from effects. 4. Craving or strong desire or urge to use the substance 5. Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home. 6. Continued substance use despite having persistent or recurrent social or interpersonal problem caused or exacerbated by the effects of the substance. 7. Important social, occupational or recreational activities given up or reduced because of substance use. 8. Recurrent substance use in situations in which it is physically hazardous. 9. Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. 10. Tolerance, as defined by either of the following: a. Markedly increased amounts of the substance in order to achieve intoxication or desired effect; Which:__________________________________________ b. Markedly diminished effect with continued use of the same amount; Which:___________________________________________ 11. Withdrawal, as manifested by either of the following: a. The characteristic withdrawal syndrome for the substance; Which:___________________________________________ b.
    [Show full text]
  • ADHD: Substance Abuse
    1/13/2012 Overview of Mental Health Medications for Children and Adolescents Module 6 Medications and Drugs of Abuse 1 1967 Now Alcohol Alcohol Marijuana Marijuana Cocaine Cocaine Methamphetamine Crank LSD LSD Rohypnol/GHB Quaaludes Inhalants Glue Ecstasy Designer drugs Prescription drugs 2 ADHD: Substance Abuse Children with untreated ADHD are twice as likely to develop substance abuse by age 18-20 than those who were treated Treatment with stimulants in adolescents with ADHD and comorbid substance abuse improves the ADHD and does not worsen the substance abuse disorder 3 1 1/13/2012 Drug Lingo Resources www.noslang.com www.teenchatterdecoder.com 4 2001 2003 2004 2008 Cocaine 967.6 kg 379.6 1308.1 1016.1 kg kg kg Heroin 15.8 kg 60 kg 39.3 kg 3.3 kg Meth 77.4 kg 88 kg 83.9 kg 65 kg Meth Labs 51 226 261 78 Ecstasy Tablets 52951 8393 5 Cocaine Bulk cocaine transported into state – crack made locally Primary sources – Texas and California Heroin Sources of supply – Chicago, New York and Southwest Purity in GA ranges between 52-65% Greater Hispanic involvement www.dea.gov 6 2 1/13/2012 Drug Use in Georgia Methamphetamine Atlanta, Dalton, Gainesville showing increases as well as southwest and eastern counties Increased availability of ICE in Atlanta area Club drugs MDMA, GHB and ketamine readily available (gyms, college campuses and associated ‘hang outs’ LSD usually around school settings – imported from West Coast by US postal service or express mail Emerging trend – ‘candy tripping’ – combining LSD and MDMA
    [Show full text]
  • Appendix D: Important Facts About Alcohol and Drugs
    APPENDICES APPENDIX D. IMPORTANT FACTS ABOUT ALCOHOL AND DRUGS Appendix D outlines important facts about the following substances: $ Alcohol $ Cocaine $ GHB (gamma-hydroxybutyric acid) $ Heroin $ Inhalants $ Ketamine $ LSD (lysergic acid diethylamide) $ Marijuana (Cannabis) $ MDMA (Ecstasy) $ Mescaline (Peyote) $ Methamphetamine $ Over-the-counter Cough/Cold Medicines (Dextromethorphan or DXM) $ PCP (Phencyclidine) $ Prescription Opioids $ Prescription Sedatives (Tranquilizers, Depressants) $ Prescription Stimulants $ Psilocybin $ Rohypnol® (Flunitrazepam) $ Salvia $ Steroids (Anabolic) $ Synthetic Cannabinoids (“K2”/”Spice”) $ Synthetic Cathinones (“Bath Salts”) PAGE | 53 Sources cited in this Appendix are: $ Drug Enforcement Administration’s Drug Facts Sheets1 $ Inhalant Addiction Treatment’s Dangers of Mixing Inhalants with Alcohol and Other Drugs2 $ National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) Alcohol’s Effects on the Body3 $ National Institute on Drug Abuse’s (NIDA’s) Commonly Abused Drugs4 $ NIDA’s Treatment for Alcohol Problems: Finding and Getting Help5 $ National Institutes of Health (NIH) National Library of Medicine’s Alcohol Withdrawal6 $ Rohypnol® Abuse Treatment FAQs7 $ Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Keeping Youth Drug Free8 $ SAMHSA’s Center for Behavioral Health Statistics and Quality’s (CBHSQ’s) Results from the 2015 National Survey on Drug Use and Health: Detailed Tables9 The substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15.10 Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States, their relative abuse potential, and likelihood of causing dependence when abused.
    [Show full text]
  • A Molecular Phylogeny of the Solanaceae
    TAXON 57 (4) • November 2008: 1159–1181 Olmstead & al. • Molecular phylogeny of Solanaceae MOLECULAR PHYLOGENETICS A molecular phylogeny of the Solanaceae Richard G. Olmstead1*, Lynn Bohs2, Hala Abdel Migid1,3, Eugenio Santiago-Valentin1,4, Vicente F. Garcia1,5 & Sarah M. Collier1,6 1 Department of Biology, University of Washington, Seattle, Washington 98195, U.S.A. *olmstead@ u.washington.edu (author for correspondence) 2 Department of Biology, University of Utah, Salt Lake City, Utah 84112, U.S.A. 3 Present address: Botany Department, Faculty of Science, Mansoura University, Mansoura, Egypt 4 Present address: Jardin Botanico de Puerto Rico, Universidad de Puerto Rico, Apartado Postal 364984, San Juan 00936, Puerto Rico 5 Present address: Department of Integrative Biology, 3060 Valley Life Sciences Building, University of California, Berkeley, California 94720, U.S.A. 6 Present address: Department of Plant Breeding and Genetics, Cornell University, Ithaca, New York 14853, U.S.A. A phylogeny of Solanaceae is presented based on the chloroplast DNA regions ndhF and trnLF. With 89 genera and 190 species included, this represents a nearly comprehensive genus-level sampling and provides a framework phylogeny for the entire family that helps integrate many previously-published phylogenetic studies within So- lanaceae. The four genera comprising the family Goetzeaceae and the monotypic families Duckeodendraceae, Nolanaceae, and Sclerophylaceae, often recognized in traditional classifications, are shown to be included in Solanaceae. The current results corroborate previous studies that identify a monophyletic subfamily Solanoideae and the more inclusive “x = 12” clade, which includes Nicotiana and the Australian tribe Anthocercideae. These results also provide greater resolution among lineages within Solanoideae, confirming Jaltomata as sister to Solanum and identifying a clade comprised primarily of tribes Capsiceae (Capsicum and Lycianthes) and Physaleae.
    [Show full text]
  • How to Anesthetize Donkeys for Surgical Procedures in the Field
    DRUGS AND ANESTHESIA How to Anesthetize Donkeys for Surgical Procedures in the Field Lori A. Bidwell, DVM, Diplomate ACVA Author’s address: Ross University School of Veterinary Medicine, PO Box 334, St. Kitts, West Indies; e-mail: [email protected]. © 2010 AAEP. 1. Introduction ing a local block where a catheter will be placed and Donkeys are an important part of the work force in making a small skin incision with a surgical blade much of the world. Practitioners working with before placing an intravenous catheter is recom- donkeys in the United States and those participat- mended. Intubation is more difficult because of ing in equitarian initiatives abroad should under- caudal angulation of the larynx, a pharyngeal diver- stand the difference between donkeys and horses in ticulum, excess pharyngeal mucosa, and long paired relation to anesthesia. Although it is tempting to laryngeal saccules. Additionally, nasal intubation 1 treat a donkey like a horse, there are important is complicated by narrow nasal passages. Drug differences in relation to handling and drug doses. metabolism is elevated in donkeys compared with Additionally, it is important to understand alterna- horses, resulting in the use of higher doses and more 2–6 tive anesthetic protocols because a practitioner may frequent dosing intervals. The only known ex- be limited to minimal or alternative drugs when ception to this is the administration of guaifenesin, working in a developing country. which seems to require lower dosing because respi- ratory arrest is easy to achieve when using doses 7 2. Behavior and Physiology appropriate for a horse. A tame donkey can be easy to handle but a feral or minimally handled donkey can be frustrating.
    [Show full text]
  • Opioid Use Disorders
    AD APTING YOUR PRACTIC E Recommendations for the Care of Homeless Patients with Opioid Use Disorders Opioid Use Disorders March 2014 ADAPTING YOUR PRACTICE Recommendations for the Care of Homeless Patients with Opioid Use Disorders Health Care for the Homeless Clinicians’ Network March 2014 Health Care for the Homeless Clinicians’ Network Adapting Your Practice: Recommendations for the Care of Homeless Patients with Opioid Use Disorders was developed with support from the Bureau of Primary Health Care, Health Resources and Services Administration, U.S. Department of Health and Human Services. All material in this document is in the public domain and may be used and reprinted without special permission. Citation as to source, however, is appreciated. Suggested citation: Meges D, Zevin B, Cookson E, Bascelli L, Denning P, Little J, Doe-Simkins M, Wheeler E, Watlov Phillips S, Bhalla P, Nance M, Cobb G, Tankanow J, Williamson J, Post P (Ed.). Adapting Your Practice: Recommendations for the Care of Homeless Patients with Opioid Use Disorders. 102 pages. Nashville: Health Care for the Homeless Clinicians' Network, National Health Care for the Homeless Council, Inc., 2014. DISCLAIMER This publication was made possible by grant number U30CS09746 from the Health Resources & Services Administration, Bureau of Primary Health Care. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Health Resources & Services Administration. i ADAPTING YOUR PRACTICE Recommendations for the Care of Homeless Patients with Opioid Use Disorders Health Care for the Homeless Clinicians’ Network PREFACE Clinicians experienced in homeless health care routinely adapt their practice to foster better outcomes for their patients.
    [Show full text]
  • 3.2.1.2 Lean Pre-Mixed Combustion 3.2.1.2-1 Introduction
    3.2.1.2 Lean Pre-Mixed Combustion 3.2.1.2-1 Introduction Gas turbine designers are continually challenged to improve cycle effi ciency while maintaining or reducing emissions. This challenge is made more diffi cult by the fact that these are often confl icting goals. The path to improved effi ciency is higher working fl uid temperatures, but higher temperatures promote NOx formation and at 2,800 F the threshold for thermal NOx formation is reached. Furthermore, reducing available oxygen to reduce NOx can result in higher carbon monoxide (CO) and unburned hydrocarbon emissions due to incomplete combustion. Moreover, increasing fi ring temperatures above 2,350 F represents a signifi cant materials science challenge.1 To achieve lower pollutant emission rates, a variety of pre-formation and post- formation control technologies have been utilized either individually or in combination, including: • Wet controls (water or steam injection) • Dry combustion controls (lean combustion, reduced residence time, lean premixed combustion, and two-stage rich/lean combustion) • Selective catalytic reduction • SCONOX catalytic absorption • Catalytic combustion (e.g. Xonontm ) • Rich Quench Lean Combustors • CO oxidation catalysts This section of the Handbook focuses on Lean Premixed (LPM) combustion, a pre-formation control strategy that has become the standard technique employed by gas turbine original equipment manufacturers (OEM), particularly for natural gas applications. OEMs have developed processes that use air as a diluent to reduce combustion fl ame temperatures and reduce NOx by premixing fuel and air before they enter the combustor. This lean premixed combustion process is referred to by a variety of trade names including General Electric’s and Siemens-Westinghouse’s Dry Low NOx (DLN) processes, Rolls-Royce’s Dry Low Emissions (DLE) process and Solar Turbines’ SoLo NOx process.
    [Show full text]
  • HHS Guide for Clinicians on the Appropriate Dosage Reduction Or
    This HHS Guide for Clinicians on the Appropriate Dosage HHS Guide for Clinicians on the Reduction or Discontinuation of Long-Term Opioid Analgesics provides advice to clinicians who are contemplating or initiating a reduction in opioid dosage or discontinuation Appropriate Dosage Reduction of long-term opioid therapy for chronic pain. In each case the clinician should review the risks and benefits of the or Discontinuation of current therapy with the patient, and decide if tapering is appropriate based on individual circumstances. Long-Term Opioid Analgesics After increasing every year for more than a decade, annual needs.2,3,4 Coordination across the health care team is critical. opioid prescriptions in the United States peaked at 255 million in Clinicians have a responsibility to provide or arrange for 2012 and then decreased to 191 million in 2017.i More judicious coordinated management of patients’ pain and opioid-related opioid analgesic prescribing can benefit individual patients as problems, and they should never abandon patients.2 More well as public health when opioid analgesic use is limited to specific guidance follows, compiled from published guidelines situations where benefits of opioids are likely to outweigh risks. (the CDC Guideline for Prescribing Opioids for Chronic Pain2 At the same time opioid analgesic prescribing changes, such and the VA/DoD Clinical Practice Guideline for Opioid Therapy as dose escalation, dose reduction or discontinuation of long- for Chronic Pain3) and from practices endorsed in the peer- term opioid analgesics, have potential to harm or put patients at reviewed literature. risk if not made in a thoughtful, deliberative, collaborative, and measured manner.
    [Show full text]
  • Role and Advantageousness of Ketamine
    a & hesi C st lin e ic n a A l Journal of Anesthesia and Clinical f R o e l s e a a n Weinbroum, J Anesth Clin Res 2018, 9:5 r r c u h o J Research DOI: 10.4172/2155-6148.1000827 ISSN: 2155-6148 Review Article Open Access Role and Advantageousness of Ketamine in Obese and Non-Obese Patients: Peri-Interventional Considerations Avi A Weinbroum* Department of Research and Development, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel *Corresponding author: Avi A Weinbroum, Department of Research and Development, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel: +972-3-5440904; E-mail: [email protected] Received date: May 16, 2018; Accepted date: May 25, 2018; Published date: May 29, 2018 Copyright: ©2018 Weinbroum AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Obese and morbidly obese patients are a growing group of individuals that generates medical, social and economic problems worldwide. They undergo various interventions that require anesthesia and/or analgesia. Despite their healthy look, these individuals are graded at high ASA physical status, mainly because of their impaired respiratory and cardiovascular conditions, and the metabolic changes their body undergoes. Opioids are the default drugs for perioperative analgesia. Nevertheless, their use has reached a frightening epidemic-like condition worldwide.
    [Show full text]